78. Translating lab insights for outcomes to cancer patients, Heike Keilhack, CSO,Ribon Therapeutics
Dr. Keilhack is an accomplished cancer biologist with rich experience in cell biology, animal models of cancer, pharmacology and translational medicine with over 15 years of experience in oncology dru...
3 Nov 202129min
77. Battling rare diseases: patients and scientists, Ethan Perlstein, Founder and CEO, Perlara
Dr. Ethan Perlstein is the founder and CEO of Perlara PBC, the first biotech public benefit company established in 2014 that partners with highly motivated and entrepreneurial families and foundations...
27 Okt 202126min
76. Advancing immuno-oncology, Michel Detheux, President and CEO, iTeos Therapeutics
Michel Detheux is the co-founder, President, and CEO of iTeos Therapeutics, and has held the role of CEO since the company’s inception in 2012. He previously served as a director at Ludwig Cancer Rese...
20 Okt 202121min
75. Innovations in cell therapies via microfluidics, Armon Sharei, CEO and Founder, SQZ Biotech
Armon Sharei, PhD, is the Chief Executive Officer and Founder of SQZ Biotechnologies, a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients arou...
13 Okt 202130min
74. Pioneering circular oRNA therapeutics, Thomas Barnes, Chief Executive Officer, Orna Therapeutics
Thomas is a veteran entrepreneur who has turned creative scientific visions into successful businesses for both startups and established organizations for over 20 years and has co-founded or helped la...
6 Okt 202124min
73. Patient focused gene editing for heart disease, Andrew Bellinger, CSO/CMO, Verve Therapeutics
Andrew Bellinger is chief scientific officer of Verve Therapeutics. He is a general cardiologist at Brigham and Women’s Hospital and is board-certified in cardiovascular medicine and internal medicine...
29 Sep 202122min
72. Unlocking biologic drug production, Brian Finrow, Co-Founder and CEO, Lumen Bioscience
Brian Finrow brings the skills and experience of a lawyer to a position that, in the biotech world, is more typically occupied by a scientist. This is essential to an enterprise like Lumen, which is r...
22 Sep 202120min
71. Leadership in immuno-oncology, Jeffrey Goldberg, President and CEO, Immunitas Therapeutics
Jeffrey Goldberg is the president and CEO of Immunitas. Jeff is an experienced biotech program and brand leader with over 20 years of industry experience. He has driven programs from discovery and pre...
15 Sep 202121min
